Sandip I. Patel - Apr 25, 2025 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director
Signature
/s/ Torsten Hombeck, as Attorney-in-Fact
Stock symbol
AKTX
Transactions as of
Apr 25, 2025
Transactions value $
$149,997
Form type
4
Date filed
4/29/2025, 05:00 PM
Previous filing
Mar 24, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKTX American Depositary Shares representing Ordinary Shares Award $50K +44.6K +9.88% $1.12 496K Mar 6, 2025 Direct F1, F2
holding AKTX American Depositary Shares representing Ordinary Shares 6.25K Apr 25, 2025 TT Insurance Investment LLC F1
holding AKTX American Depositary Shares representing Ordinary Shares 13.9K Apr 25, 2025 Innovative Lifesci Investments LLC F1
holding AKTX American Depositary Shares representing Ordinary Shares 19.9K Apr 25, 2025 Quest Bio LLC F1
holding AKTX American Depositary Shares representing Ordinary Shares 20.2K Apr 25, 2025 Davis Island Ventures LLC F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKTX Series A Warrants (Right to Buy) Award $50K +44.6K $1.12 44.6K Mar 6, 2025 American Depositary Shares representing Ordinary Shares 44.6K $0.87 Direct F1, F2
transaction AKTX Series B Warrants (Right to Buy) Award $50K +44.6K $1.12 44.6K Mar 6, 2025 American Depositary Shares representing Ordinary Shares 44.6K $0.87 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.
F2 On April 25, 2025, the Reporting Person acquired 44,642 ADS and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant.